- The total Finnish pharmaceutical market grew by 12.1%.
- Net sales amounted to EUR 672.2 million.
- Tamro Finland's foremost aim in 2002 is to increase productivity,
cost-efficiency and maintain service quality at a high level.
Operating environment and markets
The total Finnish pharmaceutical market grew by 12.1%. Overall
pharmaceutical sales by wholesalers stood at EUR 1,294 million
and the competitive situation remained tight. Tamro's share
of drug sales by wholesalers diminished to under 50%. In spite
of this, Tamro Finland remained a market leader.
At the end of the year the Ministry of Social Affairs and
Health started preparing a national pharmaceuticals strategy.
Among other issues, the Ministry will look at the costs and
financing of medical treatment, the availability of pharmaceuticals,
the distribution system and the benefits of IT in pharmaceuticals
management.
Financial performance and operations
In the year under review six significant cooperation contracts
with the pharmaceutical industry were extended, while one
important partner was lost, the effects of which will be felt
in 2002.
Tamro Finland continued to undergo major changes in 2001.
The information system introduced in the previous year was
upgraded in March to enhance its euro readiness and improve
its stability and manageability. Tamro Finland entered the
euro era smoothly.
The biggest logistic change was the completion of the new
Tampere regional service centre and its gradual introduction
starting in June. The former distribution centre was closed
in the end of August. As volumes grew at the new service centre,
unexpected technical problems came up and further changes
had to be rescheduled. This caused extra labour costs in other
service centres which erased the cost benefit obtained as
a result of staff reductions in the previous year and turned
the company's profit into a loss in 3Q, and with a severe
full year impact.
In summer Tamro Finland's warehouse operations were divided
between Tamro House's central warehouse and the distribution
warehouses of the regional service centres. This streamlining
will make it easier to monitor inventory values.
The Pharmakon Unit, which belongs to Tamro Finland, markets
healthcare products, hygiene products and cosmetics sold at
pharmacies and natural product stores. The sales of Pharmakon
remained at the previous year's level. A comprehensive cooperation
agreement was concluded with the University Pharmacy concerning
the sale of certain products marketed by different companies
and of products represented by Pharmakon. The contract was
renewed and its scope extended for 2002.
Organisation change
Mr Jorma Turunen was appointed Managing Director of both
Tamro's pharmaceutical wholesale trade in Finland and the
Tamro MedLab group as of 14 December 2001. Furthermore, Mr
Stefan Pflug, Group Logistics Director, was appointed also
Logistics Director for Tamro Finland.
Outlook for 2002
Prospects are favourable for the pharmaceutical market also
in 2002, but the present tough competitive situation in the
wholesale trade is expected to continue. Tamro Finland's foremost
aim in 2002 is to increase productivity, cost-efficiency and
maintain service quality at a high level. Statutory negotiations
due to the plans to concentrate Tamro Finland's distribution
and customer service operations to Tampere and decrease the
amount of employees started in January 2002.
|